Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.62EUR
23 May 2018
Change (% chg)

€0.00 (+0.06%)
Prev Close
€1.62
Open
€1.61
Day's High
€1.62
Day's Low
€1.60
Volume
387,335
Avg. Vol
994,215
52-wk High
€4.26
52-wk Low
€1.45

Chart for

About

Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical... (more)

Overall

Beta: 1.53
Market Cap(Mil.): €690.21
Shares Outstanding(Mil.): 222.65
Dividend: --
Yield (%): --

Financials

  PHMR.MC Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -0.08 -- --
ROI: -13.41 14.84 14.38
ROE: -33.49 16.34 16.07

BRIEF-Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY

* FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO

28 Feb 2018

BRIEF-Pharma Mar Announces Positive Results Of Its MI13004 Antibody Conjugate

* ANNOUNCES POSITIVE RESULTS OF ITS ANTIBODY CONJUGATE ACTIVE IN BREAST, OVARIAN AND GASTRIC CANCERS Source text for Eikon:

16 Feb 2018

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

14 Feb 2018

BRIEF-Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint

* CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT Source text for Eikon:

18 Jan 2018

BRIEF-Pharma Mar Requests Re-Examination Process For Aplidin From EMA

* REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA)

03 Jan 2018

BRIEF-Pharma Mar Signs Distribution License Agreement For Aplidin In Israel

* SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

02 Jan 2018

BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

* THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA

15 Dec 2017

BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma

* SAYS PRESENTS POSITIVE RESULTS OF ADMYRE PHASE III TRIAL OF PLITIDEPSIN IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Dec 2017

Earnings vs. Estimates